3:26-cv-04101
Astellas Pharma Inc v. DR Reddy's Laboratories Inc
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Astellas Pharma Inc. (Japan); Astellas US LLC (Delaware); Astellas Pharma US, Inc. (Delaware); Medivation LLC (Delaware); Medivation Prostate Therapeutics LLC (Delaware)
- Defendant: Dr. Reddy's Laboratories, Inc. (New Jersey)
- Plaintiff's Counsel: Walsh Pizzi Oreilly Falanga LLP
- Case Identification: 3:26-cv-04101, D.N.J., 04/17/2026
- Venue Allegations: Venue is alleged to be proper as to Defendant Dr. Reddy's Laboratories, Inc. because it is incorporated and resides in New Jersey. Venue is alleged to be proper as to Defendant Dr. Reddy's Laboratories Limited because it is a foreign corporation that may be sued in any judicial district.
- Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market generic versions of the prostate cancer drug Xtandi® constitutes an act of infringement of four U.S. patents covering formulations and methods of use for the active ingredient, enzalutamide.
- Technical Context: The technology concerns pharmaceutical formulations designed to improve the solubility and bioavailability of enzalutamide, an androgen receptor inhibitor used in the treatment of prostate cancer, a major segment of the oncology market.
- Key Procedural History: This action was initiated under the Hatch-Waxman Act following Plaintiffs' receipt of a notice letter dated March 4, 2026, in which Defendants stated they had filed ANDA No. 221187 with the U.S. Food and Drug Administration (FDA). The notice included a "Paragraph IV" certification asserting that the patents-in-suit are invalid, unenforceable, and/or not infringed by the proposed generic product.
Case Timeline
| Date | Event |
|---|---|
| 2012-09-11 | Priority Date for '689, '357, and '128 Patents |
| 2015-08-12 | Priority Date for '628 Patent |
| 2020-08-04 | FDA approves NDA No. 213674 for Xtandi® tablets |
| 2023-11-16 | FDA approves expanded indication for Xtandi® tablets |
| 2023-12-12 | U.S. Patent No. 11,839,689 Issues |
| 2024-12-10 | U.S. Patent No. 12,161,628 Issues |
| 2025-10-21 | U.S. Patent No. 12,447,128 Issues |
| 2025-12-23 | U.S. Patent No. 12,502,357 Issues |
| 2026-03-04 | Date of DRL Notice Letter to Plaintiffs |
| 2026-04-17 | Complaint Filing Date |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 11,839,689
- Patent Identification: U.S. Patent No. 11,839,689 ("the '689 patent"), titled "Formulations of Enzalutamide," issued December 12, 2023 Compl. ¶26
The Invention Explained
- Problem Addressed: The active ingredient enzalutamide is effective for treating conditions like prostate cancer but has very low aqueous solubility, which can limit its absorption and oral bioavailability when administered in its more stable crystalline form '689 Patent, col. 2:45-53
- The Patented Solution: The invention is a pharmaceutical composition that stabilizes enzalutamide in its more soluble, amorphous (non-crystalline) state. It achieves this by creating a "solid dispersion" where amorphous enzalutamide is mixed with a specific concentration-enhancing polymer, hydroxypropyl methylcellulose acetate succinate (HPMCAS) '689 Patent, col. 3:41-44 This formulation is designed to dissolve more quickly and to a greater extent, thereby improving the drug's effectiveness when taken orally '689 Patent, col. 2:18-24 '689 Patent, col. 2:49-53 The patent's Figure 1 provides powder X-ray diffraction (PXRD) data to visually demonstrate the amorphous, non-crystalline nature of the spray-dried dispersions compared to the sharp peaks of the bulk crystalline drug '689 Patent, Fig. 1
- Technical Importance: Creating stable amorphous solid dispersions is a critical and widely used strategy in modern pharmaceutics to overcome the common problem of poor drug solubility, enabling the development of effective oral dosage forms for many otherwise difficult-to-formulate compounds.
Key Claims at a Glance
- The complaint asserts infringement of Claim 1 Compl. ¶50
- The essential elements of independent Claim 1 are:
- a pharmaceutical composition comprising a solid dispersion
- consisting essentially of amorphous enzalutamide
- and hydroxypropyl methylcellulose acetate succinate" ("HPMCAS")
- The complaint notes that certain dependent claims specify that the formulation is a tablet Compl. ¶50
U.S. Patent No. 12,161,628
- Patent Identification: U.S. Patent No. 12,161,628 ("the '628 patent"), titled "Combination Therapy," issued December 10, 2024 Compl. ¶28
The Invention Explained
- Problem Addressed: The patent addresses a drug-drug interaction. Enzalutamide metabolism is affected by other drugs that induce the CYP3A4 enzyme. When a patient takes a strong CYP3A4 inducer, such as the antibiotic rifampin, it accelerates the breakdown of enzalutamide, decreasing its plasma concentration and potentially reducing its therapeutic effect '628 Patent, col. 2:1-6
- The Patented Solution: The invention provides a specific dose-adjustment method to counteract this effect. It claims a method of treating a prostate cancer patient who is also taking rifampin, which involves "co-administering" an increased daily dose of 240 mg of enzalutamide, up from the standard 160 mg dose '628 Patent, claim 1 '628 Patent, col. 2:7-17 This higher dose is intended to maintain a therapeutically effective concentration of enzalutamide in the patient's plasma despite the increased metabolism caused by rifampin.
- Technical Importance: Proactively defining dose adjustments for known drug-drug interactions is a key aspect of drug development and labeling, ensuring patient safety and predictable efficacy when a drug is used as part of a complex, multi-drug regimen.
Key Claims at a Glance
- The complaint asserts infringement of Claim 1 Compl. ¶66
- The essential elements of independent Claim 1 are:
- a method of treating prostate cancer in a patient
- to whom rifampin is administered,
- comprising co-administering to the patient a daily dose of 240 mg of enzalutamide.
- The complaint does not specify assertion of any dependent claims.
Multi-Patent Capsule: U.S. Patent No. 12,502,357
- Patent Identification: U.S. Patent No. 12,502,357 ("the '357 patent"), titled "Formulations of Enzalutamide," issued December 23, 2025 Compl. ¶30
- Technology Synopsis: This patent claims a method of treating prostate cancer by administering a tablet form of the enzalutamide formulation Compl. ¶89 The tablet comprises a "solid dispersion comprising amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate," addressing the same solubility and bioavailability problem as the '689 patent Compl. ¶89
- Asserted Claims: Claim 1 Compl. ¶89
- Accused Features: The accused feature is the anticipated use of DRL's proposed generic tablets to treat prostate cancer, which the complaint alleges will be prescribed and administered for that purpose Compl. ¶93 Compl. ¶97
Multi-Patent Capsule: U.S. Patent No. 12,447,128
- Patent Identification: U.S. Patent No. 12,447,128 ("the '128 patent"), titled "Formulations of Enzalutamide," issued October 21, 2025 Compl. ¶32
- Technology Synopsis: This patent claims a method of treating prostate cancer by orally administering two tablets, each comprising a specific formulation of 80 mg amorphous enzalutamide in a spray-dried dispersion with HPMCAS Compl. ¶108 A key aspect of the invention is a stability requirement: the amorphous enzalutamide must remain in its amorphous state after being stored for one month at 40° C. and 75% relative humidity, addressing the technical challenge of preventing the more-soluble amorphous form from reverting to its less-soluble crystalline state '128 Patent, claim 1
- Asserted Claims: Claim 3 Compl. ¶108
- Accused Features: The accused feature is the anticipated prescription and administration of DRL's 80 mg generic tablets to treat prostate cancer, which the complaint alleges will comprise the claimed dispersion and meet the claimed stability requirement Compl. ¶111 Compl. ¶112
III. The Accused Instrumentality
Product Identification
The accused instrumentalities are "DRL's Generic Products," which are the proposed generic enzalutamide tablets, in 40 mg and 80 mg strengths, for which Defendant Dr. Reddy's sought FDA approval via ANDA No. 221187 Compl. ¶40 Compl. ¶41
Functionality and Market Context
The complaint alleges that DRL's Generic Products are generic versions of Plaintiffs' Xtandi® tablets and are intended for the same indications: treatment of castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer Compl. ¶41 Compl. ¶42 The central "act of infringement" is the filing of the ANDA itself, which seeks approval to manufacture, use, and sell these products before the expiration of the patents-in-suit Compl. ¶49 Based on information and belief, the complaint asserts that the proposed generic tablets will contain a solid dispersion of amorphous enzalutamide and HPMCAS, thereby copying the patented formulation Compl. ¶53 Compl. ¶55 The complaint includes a chemical structure diagram of the active ingredient, enzalutamide Compl. p. 7
IV. Analysis of Infringement Allegations
'689 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| a pharmaceutical composition comprising a solid dispersion | DRL's Generic Products are tablets that will contain a pharmaceutical composition comprising a solid dispersion. | ¶52; ¶55 | col. 3:41-42 |
| consisting essentially of amorphous enzalutamide | The solid dispersion in DRL's Generic Products will consist essentially of amorphous enzalutamide. | ¶55 | col. 2:45-46 |
| and hydroxypropyl methylcellulose acetate succinate" ("HPMCAS") | The solid dispersion in DRL's Generic Products will consist essentially of HPMCAS. | ¶55 | col. 3:42-44 |
'628 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| a method of treating prostate cancer in a patient | The proposed labeling for DRL's Generic Products will direct their use for the treatment of prostate cancer. | ¶68 | col. 1:15-19 |
| to whom rifampin is administered, | The proposed labeling will identify rifampin as a drug that interacts with enzalutamide and direct co-administration in patients receiving it. | ¶68 | col. 2:1-6 |
| comprising co-administering to the patient a daily dose of 240 mg of enzalutamide. | The proposed labeling will direct a dose of 240 mg of enzalutamide for patients who are also receiving rifampin. | ¶68 | col. 2:15-17 |
- Identified Points of Contention:
- Scope Questions ('689 Patent): A primary issue for the composition claim in the '689 patent will be the scope of the phrase "consisting essentially of." Infringement will depend on whether DRL's proposed generic product contains any unlisted ingredients within its solid dispersion that materially alter the basic and novel properties (i.e., solubility enhancement and stability) of the claimed two-part composition.
- Evidentiary Questions ('628 Patent): For the method claim of the '628 patent, infringement is based on inducement. The central question will be evidentiary: does the precise language in DRL's proposed product label, as submitted in its confidential ANDA, actually instruct, encourage, or promote the specific act of administering a 240 mg daily dose of enzalutamide to a patient who is also taking rifampin? The complaint's allegation is made on "information and belief" and will require evidence from the ANDA itself Compl. ¶68
V. Key Claim Terms for Construction
'689 Patent
- The Term: "consisting essentially of" (from Claim 1)
- Context and Importance: This transitional phrase is a term of art in patent law that is broader than "consisting of" but narrower than "comprising." The infringement analysis for the '689 patent will turn on whether any additional, unrecited substances in the Defendants' solid dispersion "materially affect the basic and novel properties" of the claimed invention. Practitioners may focus on this term because the composition of a generic formulation is the central issue in ANDA litigation.
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The specification broadly describes the invention as improving the solubility and absorption of enzalutamide through a solid dispersion, suggesting the "basic and novel properties" relate to this functional outcome '689 Patent, col. 2:18-24 This could support an interpretation where unrecited excipients that do not interfere with this solubility enhancement are permissible.
- Evidence for a Narrower Interpretation: The patent repeatedly emphasizes the two-component system of amorphous enzalutamide and a concentration-enhancing polymer '689 Patent, col. 3:41-44 The specific examples focus almost exclusively on these two components, which may support a narrower reading where the "basic and novel properties" are tied to the specific dissolution profiles and stability characteristics achieved by the recited two-component blend alone.
'628 Patent
- The Term: "co-administering" (from Claim 1)
- Context and Importance: The definition of this term is critical for determining what actions constitute infringement of this method claim. Its construction will establish the required temporal relationship between the administration of enzalutamide and rifampin. Practitioners may focus on this term because the specifics of a physician's prescription and a patient's compliance, as encouraged by a drug label, will be measured against this definition to determine inducement.
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The patent discusses managing a drug-drug interaction that affects plasma concentrations over time, not just at a single moment '628 Patent, col. 2:1-6 This context may support a broader interpretation where "co-administering" refers to the concurrent therapeutic use of both drugs as part of a patient's overall treatment regimen, without requiring simultaneous intake.
- Evidence for a Narrower Interpretation: The patent does not provide an explicit definition for the term, so it would likely be given its plain and ordinary meaning. A defendant could argue that the term implies a more direct and proximate administration schedule than simply being on both drugs concurrently. However, the specification lacks language to strongly support a definition narrower than the conventional understanding in pharmacology.
VI. Other Allegations
Indirect Infringement: The complaint alleges active inducement of infringement under 35 U.S.C. § 271(b) for the method claims of the '628, '357, and '128 patents. The basis for these allegations is that DRL's proposed product labeling will instruct and encourage physicians and patients to use the generic product in an infringing manner Compl. ¶68 Compl. ¶96 Compl. ¶115 The complaint also alleges contributory infringement under 35 U.S.C. § 271(c) for the '357 and '128 patents, asserting that DRL's products are especially made for an infringing use and are not staple articles of commerce suitable for substantial non-infringing use Compl. ¶94 Compl. ¶113 Compl. ¶121
Willful Infringement: The complaint does not use the term "willful infringement" but does state that the case is "exceptional" and requests an award of attorney fees under 35 U.S.C. § 285 Compl., Prayer for Relief E The basis for this allegation is Defendants' alleged knowledge of the patents-in-suit, as evidenced by their reference in the DRL Notice Letter, and the assertion that Defendants' opinions regarding non-infringement are "devoid of an objective good faith basis" Compl. ¶57 Compl. ¶59 Compl. ¶95 Compl. ¶104 Compl. ¶114 Compl. ¶123
VII. Analyst's Conclusion: Key Questions for the Case
A central issue for the formulation patents ('689, '357, '128) will be one of claim scope: can the term "consisting essentially of," which defines the core two-component solid dispersion, be interpreted to read on the specific formulation disclosed in DRL's confidential ANDA, which may contain other excipients? Furthermore, the court will need to determine if DRL's product meets the specific stability and dosage requirements recited in the method claims.
A key evidentiary question for the method-of-use patents ('628, '357, '128) will be one of inducement: does the precise language within DRL's proposed product label actually instruct, encourage, or promote the specific infringing acts, such as the 240 mg dose adjustment for patients on rifampin, as required to prove that DRL intended for physicians to infringe?
Ultimately, this Hatch-Waxman action will depend on a technical comparison between the asserted claims and the detailed formulation and labeling information contained within DRL's confidential ANDA. The dispute will likely focus on whether DRL's product was designed to be identical to the patented technology or if it was designed to circumvent the claims through differences in composition or prescribed use.